Molecular Therapy as a Future Strategy in Endometrial Cancer

Abstract

Of all gynecologic cancers, endometrial cancer is the most common cancer in the US and Europe. In addition, it is presently the second most common gynecologic cancer in the world. As a result of increasing menopausal, obese and tamoxifen use women, the incidence of the cancer seems to be on the increase. Surgery is the major treatment, whereas postoperative radiation therapy in high-intermediate risk patients many prevent locoregional recurrence. Adjuvant chemotherapy can improve progression free survival in advanced or recurrent cancers. Molecular targeted therapies are now a focus of attention including anti-vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitor and tyrosine kinase inhibitor (TKI). They may provide useful future strategies for control of endometrial malignancies in developing countries and across the world.

TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma

“…In the United States, there are projected to be 49 500 new cases and 8200 deaths caused by endometrial carcinoma in this year [2]. Despite a high early diagnosis rate (>70%), more than 25% of patients with endometrial carcinoma finally present regional/distant metastasis [3,4]. To date, the main treatments for endometrial carcinoma are still surgery and/or radiation therapy, and chemotherapy is another choice for tumors at later stage or distant metastasis [5,6].…”

Expression and Effects of JMJD2A Histone Demethylase in Endometrial Carcinoma

“…Endometrial carcinoma is one of the most common gynecological malignancies (Siegel et al, 2013) and its incidence has been growth since the menopausal women populations were increasing, in western countries and China (Thanapprapasr et al, 2013). Although most endometrial carcinoma is diagnosed at an early stage, 30% of all cases are still diagnosed at later stages, which correlate with decreased survival rates (Salvesen et al, 2012).…”

The Polymorphism of Hypoxia-inducible Factor-1a Gene in Endometrial Cancer

“…It is believed that there are two different pathogenetic types of endometrial carcinomas: estrogen-dependent type I and estrogen-independent type II (Thanapprapasr and Thanapprapasr, 2013).…”